These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29446053)

  • 1. Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors.
    Vaidya T; Kamta J; Chaar M; Ande A; Ait-Oudhia S
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):401-418. PubMed ID: 29446053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity.
    Grabowska ME; Chun B; Moya R; Saucerman JJ
    J Mol Cell Cardiol; 2021 Jun; 155():66-77. PubMed ID: 33667419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes.
    Wang H; Wang Y; Li J; He Z; Boswell SA; Chung M; You F; Han S
    BMC Med; 2023 Apr; 21(1):147. PubMed ID: 37069550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.
    Ekram J; Rathore A; Avila C; Hussein R; Alomar M
    Cancer Control; 2024; 31():10732748241285755. PubMed ID: 39318033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.
    Wang H; Sheehan RP; Palmer AC; Everley RA; Boswell SA; Ron-Harel N; Ringel AE; Holton KM; Jacobson CA; Erickson AR; Maliszewski L; Haigis MC; Sorger PK
    Cell Syst; 2019 May; 8(5):412-426.e7. PubMed ID: 31078528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics.
    Shim JV; Chun B; van Hasselt JGC; Birtwistle MR; Saucerman JJ; Sobie EA
    Front Physiol; 2017; 8():651. PubMed ID: 28951721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
    Will Y; Dykens JA; Nadanaciva S; Hirakawa B; Jamieson J; Marroquin LD; Hynes J; Patyna S; Jessen BA
    Toxicol Sci; 2008 Nov; 106(1):153-61. PubMed ID: 18664550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future.
    Yang B; Papoian T
    J Appl Toxicol; 2018 Jun; 38(6):790-800. PubMed ID: 29369373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress on the cardiotoxicity of sunitinib: Prognostic significance, mechanism and protective therapies.
    Yang Y; Bu P
    Chem Biol Interact; 2016 Sep; 257():125-31. PubMed ID: 27531228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial Toxicity Associated with Imatinib and Sorafenib in Isolated Rat Heart Fibers and the Cardiomyoblast H9c2 Cell Line.
    Bouitbir J; Panajatovic MV; Krähenbühl S
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity.
    Scott SS; Greenlee AN; Matzko A; Stein M; Naughton MT; Zaramo TZ; Schwendeman EJ; Mohammad SJ; Diallo M; Revan R; Shimmin G; Tarun S; Ferrall J; Ho TH; Smith SA
    Heart Fail Clin; 2022 Jul; 18(3):425-442. PubMed ID: 35718417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug toxicity: Cardiac safety index for TKIs.
    Crunkhorn S
    Nat Rev Drug Discov; 2017 Mar; 16(4):240. PubMed ID: 28356585
    [No Abstract]   [Full Text] [Related]  

  • 16. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
    Toubert ME; Vercellino L; Faugeron I; Lussato D; Hindie E; Bousquet G
    Thyroid; 2011 Apr; 21(4):451-4. PubMed ID: 21385075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib‑ and ponatinib‑mediated cardiotoxicity in zebrafish embryos and H9c2 cardiomyoblasts.
    Zakaria ZZ; Suleiman M; Benslimane FM; Al-Badr M; Sivaraman S; Korashy HM; Ahmad F; Uddin S; Mraiche F; Yalcin HC
    Mol Med Rep; 2024 Oct; 30(4):. PubMed ID: 39219269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
    Steeghs N; Nortier JW; Gelderblom H
    Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.
    Yang B; Papoian T
    J Appl Toxicol; 2012 Dec; 32(12):945-51. PubMed ID: 22961481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.